Biotech Valuation Idiosyncrasies and Best Practices

Biotech companies with little to no revenue can still be worth billions. Consider the most prominent 2017 biotech M&A deal when Gilead bought Kite Pharma for almost $12 billion. At the time of the deal, Kite had over $600 million in accumulated deficit, but it also had a pipeline of CAR-T cell therapies, which treat cancer. This article examines how to value such pipelines. It also focuses on the risk-adjusted NPV valuation methodology, portfolios of multiple drug candidates, and how value is impacted by the characteristics of the investor or acquirer.

This site explains how a Company with no Revenue can be worth Billions , especially those with Positive Data and goes on the explain how a Valuation increases upon FDA Application / Approval
https://www.toptal.com/finance/valuation/biotech-valuation